Heart anterior exterior view. Credit: Patrick J Lynch, medical illustrator/Wikimedia.

Australia-based biotherapeutics company CSL is set to begin a Phase lll trial of CSL112 to help reduce early recurrent cardiovascular events in heart attack survivors.

The trial will be known as ApoA-I Event reducinG in Ischemic Syndromes II (AEGIS-II) and is subject to final agreement with the US Food and Drug Administration (FDA).

Related Company Profiles

View all

More than 17,000 patients from around 1,000 sites across the world will be involved in the multicentre, double-blind, randomised, placebo-controlled, parallel-group study.

AEGIS-II will assess the efficacy and safety of CSL112 to reduce the risk of cardiovascular death, myocardial infarction, and stroke in acute coronary syndrome (ACS) in patients receiving evidence-based medical therapy, diagnosed with either ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI).

"Despite recent advances in cardiovascular care, we still have an unacceptable rate of early recurrent cardiovascular events occurring in high-risk patients following an acute MI."

Harvard Medical School Medicine professor Michael Gibson will serve as the co-lead investigator of AEGIS-II, which is anticipated to take four years to complete.

Patient enrolment for the trial is expected to begin by early next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Gibson said: “Despite recent advances in cardiovascular care, we still have an unacceptable rate of early recurrent cardiovascular events occurring in high-risk patients following an acute MI.

“We are optimistic that CSL112 will offer a novel, rapid approach to reduce these events during the 90-day period when heart attack survivors are most vulnerable.”

According to the World Health Organisation’s Cardiovascular diseases (CVDs) – Fact Sheet 2017, CVD is the main cause of death across the world.

Around 54,000 people are also estimated to be hospitalised as a result of a heart attack in Australia every year.